$EIGR Eiger BioPharmaceuticals, Inc. Insider Trading Week 10/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Eiger BioPharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Eiger BioPharmaceuticals, Inc. in week 10/2020.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 5.60 | 50,000 | 280,000 | 50,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Grant | A | 7.31 | 1,500 | 10,965 | 15,921 | 14.4 K to 15.9 K (+10.40 %) |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Sachdev Amit | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Option Exercise | A | 5.60 | 65,000 | 364,000 | 65,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Ryali Sriram | Chief Financial Off ... | Grant | A | 7.31 | 229 | 1,674 | 1,628 | 1.4 K to 1.6 K (+16.37 %) |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Option Exercise | A | 5.60 | 65,000 | 364,000 | 65,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Patton Stephana Eilene | See Remarks | Grant | A | 7.31 | 820 | 5,994 | 4,820 | 4 K to 4.8 K (+20.50 %) |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Murray Christine | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Loh Evan | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Grant | A | 0.00 | 5,000 | 0 | 36,355 | 31.4 K to 36.4 K (+15.95 %) |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 5.60 | 230,000 | 1,288,000 | 230,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Grant | A | 7.31 | 1,500 | 10,965 | 69,346 | 67.8 K to 69.3 K (+2.21 %) |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Option Exercise | A | 5.60 | 20,000 | 112,000 | 20,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Dietz Thomas John | Director | Grant | A | 0.00 | 5,000 | 0 | 29,000 | 24 K to 29 K (+20.83 %) |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Option Exercise | A | 5.60 | 10,000 | 56,000 | 10,000 | |
Mar 13 2020 | EIGR | Eiger BioPharmaceu ... | Apelian David | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |